162 related articles for article (PubMed ID: 24144311)
1. Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
Firkin F
Leuk Lymphoma; 2014 May; 55(5):977-8. PubMed ID: 24144311
[No Abstract] [Full Text] [Related]
2. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Au WY; Lang BH; Fong BM; Mao KJ; Tam S
Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
[No Abstract] [Full Text] [Related]
3. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
4. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
5. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
6. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Galm O; Fabry U; Osieka R
Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
[No Abstract] [Full Text] [Related]
7. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Gupta S; Bagel B; Gujral S; Subramanian PG; Khattry N; Menon H; Nair R
Leuk Lymphoma; 2012 Nov; 53(11):2192-4. PubMed ID: 22452590
[TBL] [Abstract][Full Text] [Related]
8. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
9. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
10. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
11. Does arsenic trioxide impact fertility?
Stein EM; Tallman MS
Leuk Lymphoma; 2012 Nov; 53(11):2099-100. PubMed ID: 22524541
[No Abstract] [Full Text] [Related]
12. Scientists explore use of arsenic in therapy.
Miller M
J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
[No Abstract] [Full Text] [Related]
13. Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Huff J; Waalkes M; Nyska A; Chan P
J Natl Cancer Inst; 1999 Oct; 91(19):1690-1. PubMed ID: 10511603
[No Abstract] [Full Text] [Related]
14. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Huang CH; Chen WJ; Wu CC; Chen YC; Lee YT
Pacing Clin Electrophysiol; 1999 Jun; 22(6 Pt 1):965-7. PubMed ID: 10392399
[TBL] [Abstract][Full Text] [Related]
15. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
16. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
[TBL] [Abstract][Full Text] [Related]
17. Arsenic: a new place?
Vincent PC
Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
[No Abstract] [Full Text] [Related]
18. Arsenic compound approved as cancer chemotherapy agent.
Miller JL
Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
[No Abstract] [Full Text] [Related]
19. Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Kulkarni UP; Selvarajan S; Fouzia NA; Lionel S; Nair SC; Balasubramanian P; Mani T; Abraham A; George B; Mathews V
Blood Cancer J; 2023 Jun; 13(1):94. PubMed ID: 37349334
[No Abstract] [Full Text] [Related]
20. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
